TY - JOUR AU - Knight, Louise A. AU - Di Nicolantonio, Federica AU - Whitehouse, Pauline AU - Mercer, Stuart AU - Sharma, Sanjay AU - Glaysher, Sharon AU - Johnson, Penny AU - Cree, Ian A. PY - 2004 DA - 2004/11/23 TI - The in vitroeffect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours JO - BMC Cancer SP - 83 VL - 4 IS - 1 AB - Activation of the epidermal growth factor receptor (EGFR) triggers downstream signaling pathways that regulate many cellular processes involved in tumour survival and growth. Gefitinib ('Iressa') is an orally active tyrosine kinase inhibitor (TKI) targeted to the ATP-binding domain of EGFR (HER1; erbB1). SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-4-83 DO - 10.1186/1471-2407-4-83 ID - Knight2004 ER -